How should you counsel patients about the risk of NMSC while using ruxolitinib for vitiligo?

Featuring Benjamin Lockshin, MD | EVP of Strategic InitiativesDirector of the Clinical Trials CenterAssistant ProfessorUS Dermatology PartnersGeorgetown UniversityRockville, MD | Published July 01, 2024